About Contact Us Careers

Anti-Venom Market Analysis

Request Free Sample Copy

Report ID: 3755
Published Date: Aug 23, 2024
Report Format: PDF, PPT

Buy Now

Anti-Venom Market Analysis

The global anti-venom market is segmented by anti-venom type into polyvalent anti-venom, monovalent anti-venom, and others, out of which, the polyvalent anti-venom segment is anticipated to hold the largest share in the market on account of rising demand for polyvalent anti-venom, as they are more effective in neutralizing the effect of the venom of a broad spectrum of snakes.

Our in-depth analysis of the global market includes the following segments:

By Species	Snake Scorpion Spiders Others
By Anti-Venom Type	Polyvalent Anti-venoms Monovalent Anti-venom Others

Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:

Anti-Venom Market Size & Share, Growth Trends 2036

Author Credits: Radhika Pawar

Report ID: 3755
Published Date: Aug 23, 2024
Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of anti-venom is evaluated at USD 721.77 million.

Anti-Venom Market size was valued at USD 674.8 million in 2023 and is set to cross USD 1.99 billion by 2036, expanding at more than 8.7% CAGR during the forecast period i.e., between 2024-2036. Technological innovation in the treatment for envenoming, and rising awareness about available anti-venoms, will boost the market growth.

Asia Pacific industry is estimated to account for largest revenue share by 2036, led by growing cases of snakebites, which require anti-venom for treatment.

The major players in the market are CSL Limited, Flynn Pharma Ltd (Micropharm), Medtoxin Venom Laboratories, Merck & Co. Inc., Pfizer Inc., Rare Disease Therapeutics Inc., Amgen Inc., and others.

Inquiry Before Buying Request Free Sample